Arachidonic acid is converted to prostaglandin G 2 (PGG 2 ) by the cyclooxygenase activities of prostaglandin endoperoxide H synthases (PGHSs) 1 and 2. The initial, rate-limiting step is abstraction of the 13-proS hydrogen from arachidonate which, for PGG 2 formation, is followed by insertion of O 2 at C-11, cyclization, and a second O 2 insertion at C-15. As an accompaniment to ongoing structural studies designed to determine the orientation of arachidonate in the cyclooxygenase site, we analyzed the products formed from arachidonate by (a) solubilized, partially purified ovine (o) PGHS-1; (b) membrane-associated, recombinant oPGHS-1; and (c) a membrane-associated, recombinant active site mutant (V349L oPGHS-1) and determined kinetic values for formation of each product. Native forms of oPGHS-1 produced primarily PGG 2 but also several monohydroxy acids, which, in order of abundance, were 11R-hydroxy-5Z,8Z,12E,14Z-eicosatetraenoic acid (11R-HETE), 15S-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (15S-HETE), and 15R-HETE. V349L oPGHS-1 formed primarily PGG 2 , 15S-HETE, and 15R-HETE but only trace amounts of 11R-HETE. With native enzyme, the K m values for PGG 2 , 11-HETE, and 15-HETE formation were each different (5.5, 12.1, and 19.4 M, respectively); similarly, the K m values for PGG 2 and 15-HETE formation by V349L oPGHS-1 were different (11 and 5 M, respectively). These results establish that arachidonate can assume at least three catalytically productive arrangements within the cyclooxygenase site of oPGHS-1 leading to PGG 2 , 11R-HETE, and 15S-HETE and/or 15R-HETE, respectively. IC 50 values for inhibition of formation of the individual products by the competitive inhibitor, ibuprofen, were determined and found to be the same for a given enzyme form (i.e. 175 M for oPGHS-1 and 15 M for V349L oPGHS-1). These latter results are most simply rationalized by a kinetic model in which arachidonate forms various catalytically competent arrangements only after entering the cyclooxygenase active site.
Prostaglandin endoperoxide H synthases 1 and 2 (PGHS-1 and -2) 1 catalyze the conversion of arachidonic acid and O 2 to PGH 2 : the committed step in the formation of prostanoids (prostaglandins, thromboxane A 2 (see Refs. 1-6)). PGHS-1 (or COX-1) is often referred to as the constitutive enzyme whereas PGHS-2 (COX-2) is known as the inducible isoform (7) (8) (9) (10) (11) (12) (13) (14) (15) . Apart from their important biological roles and their functions as targets of nonsteroidal anti-inflammatory drugs (4, 5) , PGHSs are of considerable interest in the context of the structural biology and enzymology of membrane proteins. These enzymes are homodimeric (ϳ72 kDa/subunit), heme-containing, glycoproteins with two catalytic sites; moreover, PGHSs represent a prototype of a new class of integral membrane proteins that appear to be anchored to one leaflet of the lipid bilayer through the hydrophobic surfaces of amphipathic helices and not through more typical transmembrane domains (3, 16 -18) . PGHSs catalyze two separate reactions: a cyclooxygenase (bis-oxygenase) reaction in which arachidonate is converted to PGG 2 and a peroxidase reaction in which PGG 2 undergoes a two-electron reduction to PGH 2 . PGHS-1 and PGHS-2 have similar cyclooxygenase turnover numbers (ϳ3500 mol of arachidonate/min/mol of dimer; Refs. 19 -21) and K m values for arachidonate (ϳ5 M; Refs. 20 -23) and for O 2 (ϳ5 M; Refs. 24 and 25) and exhibit similar fatty acid substrate specificities (23) . The cyclooxygenase reaction begins with a rate-limiting abstraction of the 13-proS hydrogen from arachidonate to yield an arachidonyl radical (26, 27) . This is followed by sequential oxygen additions at C-11 and C-15 to yield the prostaglandin endoperoxide PGG 2 . Nonsteroidal anti-inflammatory drugs compete directly with arachidonate for binding to the cyclooxygenase site and inhibit cyclooxygenase activity, but have little or no effect on peroxidase catalysis (28 -30) .
PGHSs exhibit some lipoxygenase activity producing small amounts of 11-hydroxy-8Z,12E,14Z-eicosatrienoic acid and 15-hydroxy-8Z,11Z,13E-eicosatrienoic acid from 8,11,14-eicosatrienoic acid (26) and the corresponding 11-and 15-HETEs from arachidonic acid (31, 32) . Aspirin-acetylated PGHS-2, which has no cyclooxygenase activity, synthesizes 15R-HETE (32, 33) . Studies comparing native and aspirin-acetylated PGHS-2 have raised the possibility that arachidonate can bind in distinct orientations in the PGHS-2 active site to produce either PGG 2 plus 11R-HETE or 15R-HETE (32) . We have examined the products formed from arachidonate by native ovine (o) PGHS-1 and a cyclooxygenase active site mutant, V349L oPGHS-1, and have determined the kinetics for the formation of each individual product. We have also determined the IC 50 values for the inhibition of formation of each product by ibuprofen. Collectively, our results indicate that arachidonate can be bound in the cyclooxygenase active site of oPGHS-1 in at least three different, catalytically competent arrangements that lead to PGG 2 , 11R-HETE, and 15-HETE, respectively, and that these three arrangements of arachidonate occur subsequent to its entry into the cyclooxygenase active site.
EXPERIMENTAL PROCEDURES
Materials-Arachidonic acid was purchased from Cayman Chemical Co. (Ann Arbor, MI). [1- 14 C]Arachidonic acid (40 -60 mCi/mmol) was purchased from NEN Life Science Products. Flurbiprofen was from Sigma. Restriction enzymes and Dulbecco's modified Eagle's medium were purchased from Life Technologies, Inc. Calf serum and fetal bovine serum were purchased from HyClone. Primary antibodies used for Western blotting were raised in rabbits against purified oPGHS-1 and purified as an IgG fraction (18, 34, 35) ; goat anti-rabbit IgG horseradish peroxidase conjugate was purchased from Bio-Rad. C 10 E 7 detergent used for solubilization of oPGHS-1 was from Anatrace, Inc. Oligonucleotides used as primers for mutagenesis were prepared by the Michigan State University Macromolecular Structure and Sequencing Facility. All other reagents were from common commercial sources.
Preparation of V349L oPGHS-1-V349L oPGHS-1 was prepared starting with M13mp19-oPGHS-1, which contains a 2.3-kilobase pair SalI fragment encoding native ovine PGHS-1 (18, 34) , using a Bio-Rad Muta-Gene kit and the manufacturer's protocol. The oligonucleotide used for mutagenesis was 5Ј-1127 AGAGGAGTATCTGCAGCAGCTGA-1149 -3Ј. Single-stranded phage samples were sequenced using Sequenase (version 2.0, United States Biochemical Corp.) and the protocol described by the manufacturer. The replicative form of M13mp19-oPGHS-1 containing the V349L mutation was prepared from phage cultures, digested with SalI, isolated by gel electrophoresis, and electroluted into dialysis tubing using standard protocols. The resulting 2.3-kilobase pair oPGHS-1 cDNA fragment was purified and subcloned into pSVT7, followed by digestion with PstI to verify the orientation of the insert (18, 34, 35) . Plasmids used for transfection were purified by CsCl gradient ultracentrifugation, and the mutation was reconfirmed by double-stranded sequencing of the pSVT7 construct as described above.
Transfection of COS-1 Cells with Recombinant oPGHS-1-COS-1 cells (ATTC CRL-1650) were grown in Dulbecco's modified Eagle's medium containing 8% calf serum and 2% fetal bovine serum until near confluence (ϳ3 ϫ 10 6 cells/10-cm dish) (18, 34, 35) . Cells were then transfected with a pSVT7 plasmid containing cDNA coding for native or V349L oPGHS-1 using the DEAE-dextran/chloroquine transfection method as reported previously (18, 34, 35) . Forty hours following transfection, cells were harvested in cold phosphate-buffered saline, collected by centrifugation, and resuspended in 0.1 M Tris-HCl, pH 7.5. Shamtransfected cells were collected in an identical manner. Microsomal preparations were used for Western blotting and for cyclooxygenase and peroxidase assays.
Purification of oPGHS-1 from Seminal Vesicles 2 -Microsomes were prepared from ovine seminal vesicles essentially as described previously (36, 37) . Microsomes were solubilized with 0.1% C 10 E 7 , centrifuged, and the supernatant loaded onto an equilibrated DEAE-cellulose column. Fractions from the DEAE-cellulose column were assayed for peroxidase activity and protein concentration. Desired fractions were pooled, concentrated, and loaded onto an equilibrated S-300 column overnight. Fractions from the DEAE and S-300 columns were used for assays with partially purified enzyme. The specific cyclooxygenase activity was 2-10 units/mg for DEAE fractions and 15-30 units/mg for S300 fractions. One unit of enzyme is defined as that amount of enzyme which will catalyze the oxygenation of 1 mol of arachidonate/min.
Characterization of Arachidonate-derived Products-Forty hours following transfection, COS-1 cells were collected, sonicated, and resuspended in 0.1 M Tris-HCl, pH 7.5. Aliquots of the cell suspension (75 g of protein) or 5 cyclooxygenase activity units of partially purified oPGHS-1 were incubated for 1 min at 37°C with various concentrations of [1- 14 C]arachidonic acid with and without 200 M flurbiprofen. Radioactive products were extracted and separated by thin layer chromatography as described previously (38) . Products were visualized by autoradiography and quantitated by liquid scintillation counting. Negative control values from samples incubated with 200 M flurbiprofen were subtracted from the experimental values observed for each sample in the absence of flurbiprofen. Inhibition of product formation by ibuprofen was measured similarly using different concentrations of ibuprofen in reaction mixtures containing 10 M arachidonate.
Reverse Phase (RP)-HPLC-Native or V349L oPGHS-1 (75 g of cell protein) prepared from transfected COS cells or semipurified oPGHS-1 (5 cyclooxygenase activity units) were incubated with 2-100 M arachidonic acid for 1 min at 37°C. The products were extracted as described above and resuspended in HPLC buffers (1/1; v/v). 15-and 11-HETEs were separated by RP-HPLC using a C18 column from Vydac (Hesperia, CA) and detected with a Waters model 600 HPLC equipped with a 990 photo diode array detector set at 234 nm. The polar component of the mobile phase was 0.1% aqueous acetic acid, and the eluting solvent was acetonitrile. The flow rate was 1 ml/min. The elution profile used was: 0 -30 min, 30% acetonitrile; 30 -100 min, 50% acetonitrile; 100 -125 min, 75% acetonitrile; 125-130 min, 100% acetonitrile. The retention times of 15-HETE and 11-HETE were 36 and 38 min, respectively.
Chiral HPLC of Methyl 15-HETE and Methyl 11-HETE-Material
obtained by RP-HPLC was esterified by treatment with excess diazomethane and subjected to chiral-phase HPLC. Diazomethane was prepared from Diazald (N-methyl-N-nitroso-p-toluenesulfonamide) (Aldrich) as described in the company's technical bulletin AL-180. Chiralphase HPLC was performed on a Chiralcel OC column (250 ϫ 4.6 mm) from Daicel Chemical Industries (Osaka, Japan) using hexane/2-propanol (98/2; v/v) at a flow rate of 0.5 ml/min. The retention times of the methyl esters of 15R-and 15S-HETE were 25 and 27 min, respectively. Retention times for the methyl esters of 11R-and 11S-HETE were 26 and 28 min, respectively.
Cyclooxygenase and Peroxidase Assays-Cyclooxygenase assays were performed at 37°C by monitoring the initial rate of O 2 uptake using an oxygen electrode (39) . Each standard assay mixture contained 3.0 ml of 0.1 M Tris-HCl, pH 8.0, 1 mM phenol, 85 g of bovine hemoglobin, and 2-100 M arachidonate. Reactions were initiated by adding approximately 250 g of microsomal protein prepared from COS-1 cells or partially purified oPGHS-1 in a volume of 20 -50 l to the assay mixture. Peroxidase activity was measured spectrophotometrically as described previously (39) . The reaction mixtures contained 0.1 M Tris-HCl, pH 8.0, 0.1 mM 3,3,3Ј,3Ј-tetramethylphenylenediamine, approximately 100 g of microsomal protein, and 1.7 M hematin in a total volume of 3 ml. Reactions were initiated by adding 100 l of 0.3 mM H 2 O 2 , and the absorbance at 610 nm was monitored with time.
Kinetic Schemes and Derivations-As presented below (see "Discussion"), two different kinetic schemes were developed to model mechanisms by which oPGHS-1 could produce different products with different kinetic properties. Rate and IC 50 equations were derived for each scheme using the general rate equations below. Both schemes were developed for the formation of two separate products to illustrate the principles; however, the schemes are easily expandable to accommodate situations where there are multiple products.
The relevant rate equations for Scheme 1 are given below.
The relevant rate equations for Scheme 2 are given below.
Statistical Analysis-Results are expressed as the mean Ϯ S.E. for a minimum of four experiments using different preparations of partially purified oPGHS-1 or membrane-associated native or V349L oPGHS-1. Statistical significance was determined using a two-sample t test assuming equal variances.
RESULTS
Microsomal preparations of oPGHS-1 and V349L oPGHS-1 from COS-1 cells transfected with plasmids encoding native oPGHS-1 or V349L oPGHS-1 as well as partially purified native oPGHS-1 from seminal vesicles were used to determine overall K m values for the oxygenation of arachidonate using an oxygen electrode assay. The K m values were 3 M both for solubilized, partially purified and for membrane-associated, recombinant native oPGHS-1; as expected, this value is in the range (2-8 M) reported previously for recombinant and purified forms of ovine, murine, and human PGHS-1 (20 -23, 40) . The K m for arachidonate with the V349L oPGHS-1 mutant was 7 M. Western transfer blotting indicated that V349L oPGHS-1 was expressed in COS-1 cells at the same level as native oPGHS-1 (data not shown) and had 65% of the cyclooxygenase activity and 100% of the peroxidase activity of native oPGHS-1 expressed in parallel transfections.
As illustrated in Fig. 1 , oPGHS-1 and V349L oPGHS-1 formed the same products from [1-14 C]arachidonate including those products derived from PGG 2 (HHTre, PGD 2 , PGE 2 , and PGF 2 Љ) and the monohydroxy acids 11-hydroxy-5Z,8Z,12E, 14Z-eicosatetraenoic acid (11-HETE) and 15-hydroxy-5Z, 8Z,11Z,13E-eicosatetraenoic acid (15-HETE), which are derived from reduction of the corresponding hydroperoxides. However, V349L oPGHS-1 produced substantially larger amounts of 15-HETE and relatively less PGG 2 and 11-HETE (Fig. 1) than native enzyme. With 2 M arachidonate and 5 cyclooxygenase units of either partially purified oPGHS-1 or broken cell preparations of COS-1 cells expressing oPGHS-1, 95% of the products were derived from PGG 2 , 3% was 11-HETE, and 2% was 15-HETE; with 2 M arachidonate and broken cell preparations of COS-1 cells expressing V349L oPGHS-1, 70% of the product was PGG 2 , Ͻ0.5% was 11-HETE, and 30% was 15-HETE.
Extracts from incubation mixtures containing partially purified oPGHS-1, recombinant oPGHS-1 or recombinant V349L oPGHS-1 were incubated with different concentrations of arachidonate and then separated by RP-HPLC. 11-and 15-HETE were isolated, converted to their methyl esters, and examined by chiral HPLC. This is illustrated in Fig. 2 for   FIG. 2 . Chiral HPLC of the methyl esters of the 11-and 15-HETEs produced by native oPGHS-1. Arachidonate (100 M) was incubated with partially purified oPGHS-1 for 1 min at 37°C. 11-and 15-HETE fractions were separated by RP-HPLC and esterified by treatment with diazomethane. Chiral-phase HPLC was performed as described under "Experimental Procedures" using a Chiralcel OC column with hexane/2-propanol (98/2, v/v) as the solvent and a flow rate of 0.5 ml/min. The UV detector was set to monitor absorbance at 234 nm. A, 11(R/S)-HETE methyl ester standard; B, 11-HETE methyl ester from incubation of oPGHS-1 with arachidonate; C, coinjection of 11-HETE methyl ester from incubation of oPGHS-1 with 100 M arachidonate and 11(R/S)-HETE methyl ester standard; D, 15(R/S)-HETE methyl ester standard; E, 15-HETE methyl ester from incubation of oPGHS-1 with arachidonate; F, coinjection of 15-HETE methyl ester from incubation of oPGHS-1 with 100 M arachidonate and 15(R/S)-HETE methyl ester standard.
partially purified native oPGHS-1 incubated with 100 M arachidonate. 11-HETE was exclusively 11R-HETE. 15-HETE was 70% 15S-HETE and 30% 15R-HETE. The ratio of 15S-HETE to 15R-HETE was the same for both purified and microsomal, recombinant oPGHS-1. Similarly, the 15-HETE fraction derived from incubation of arachidonate with V349L oPGHS-1 contained 70% 15S-HETE and 30% 15R-HETE; only trace amounts of 11-HETE were formed by V349L oPGHS-1, and the chirality of this latter product was not determined. Interestingly, the enantiomeric composition of the 15-HETE product was 65-70% 15S-HETE and 30 -35% 15R-HETE at all arachidonate concentrations tested with both native and V349L oPGHS-1 (i.e. when 2, 5, 10, 20, 35, 50, or 100 M arachidonate was used as the substrate with purified oPGHS-1; when 10 and 100 M arachidonate was used as the substrate for membrane-associated, recombinant oPGHS-1; or when 2, 5, 10, 20, 35, 50, or 100 M arachidonate was used as the substrate for membrane preparations of recombinant V349L oPGHS-1).
We noted in the studies outlined above that there were obvious differences in the relative ratios of the monohydroxy fatty acid and PGG 2 -derived products at different arachidonate concentrations. Accordingly, we performed a series of measurements to determine the K m values for the formation of the different products by native oPGHS-1 (Fig. 3 ) and V349L oPGHS-1 (Fig. 4) . The results are summarized in Table I . It should be noted that the amounts of enzyme (5 units for partially purified native enzyme or 75 g of broken COS-1 cell protein for V349L oPGHS-1) used in these assays were adjusted so that Ͻ25% of the total substrate was consumed even with the lowest concentration of arachidonate tested (2 M). Product formation was analyzed after 1-min incubations by radio thin layer chromatography and/or by RP-HPLC. The key finding of these experiments is that the K m values for the formation of PGG 2 , 11-HETE, and 15-HETE by native oPGHS-1 and the K m values for PGG 2 and 15-HETE formation by V349L oPGHS-1 were different for each product (Table I) .
Because the K m values were different for the formation of each product, it was of interest to determine if the IC 50 values for the inhibition of PGG 2 , 11-HETE, and 15-HETE synthesis would be different or the same. Accordingly, we determined IC 50 values for inhibition by ibuprofen of each of the products formed by partially purified native oPGHS-1 (Fig. 5) and by the V349L oPGHS-1 mutant (Fig. 6) . Ibuprofen was chosen because it is a simple competitive, reversible cyclooxygenase inhibitor (41) . The IC 50 values for inhibition of PGG 2 , 11-HETE, and 15-HETE were the same (170 M) for native oPGHS-1; moreover, the IC 50 values for the inhibition of PGG 2 and 15-HETE formation by V349L oPGHS-1 were also identical (15 M).
DISCUSSION
There are now several x-ray crystallographic structures of PGHS-1 and -2. All of the structures reported to date have nonsteroidal anti-inflammatory drugs bound (36, 42, 43) . These crystallographic studies have defined the cyclooxygenase active site as a tunnel lined with the side chains of hydrophobic amino acids that protrudes into the core of a globular catalytic domain; the globular catalytic domain itself closely resembles that of mammalian peroxidases. We are currently addressing the question of how arachidonate itself binds within the cyclooxygenase active site at the time the rate-determining step in the reaction, abstraction of the 13-proS hydrogen (26) , occurs. These ongoing studies involve a combination of determining the crystal structure of arachidonate bound to a catalytically inactive form of oPGHS-1 with Co 3ϩ -heme substituted for Products were analyzed by RP-HPLC and/or radio thin layer chromatography as described under "Experimental Procedures." For HPLC, the amounts of products were calculated using peak areas and comparison with known amounts of PGB 2 standard. Liquid scintillation counting was used to determine the amounts of radioactive products on thin layer chromatograms. Results are from an average of eight separate experiments. A, PGG 2 -derived products (q); B, 11-HETE (E) and 15-HETE (ϫ).
Fe 3ϩ -heme and analyzing the functional effects of amino acid substitutions of cyclooxygenase active site residues. 2 In establishing a base line from which to interpret the results of these crystallographic and mutagenic analyses, it was essential to determine precisely which products are formed by oPGHS-1 under different experimental conditions. Accordingly, we characterized the products generated when arachidonic acid was incubated with native oPGHS-1 and an active site mutant, V349L oPGHS-1, and determined kinetic constants for the formation of the different products. Experiments were performed comparing partially purified with recombinant oPGHS-1 to verify that the results are applicable to solubilized and membrane-associated forms of the enzyme.
Our key finding is that the K m values for the formation of PGG 2 , 11R-HETE, and 15S/R-HETE by native oPGHS-1 differ from each other. Similarly, with V349L oPGHS-1, which forms a quantitatively different mix of products, primarily PGG 2 and 15-HETE but little 11-HETE, the K m values for formation of these products differed from one another. If the rate-determining step in the formation of the various products is, as expected (26, 44, 49) , abstraction of the 13-proS hydrogen from arachidonate, differences in K m values would only occur if there are different enzyme substrate complexes leading to the different products. The simplest interpretation of our findings is that arachidonate can assume up to three catalytically competent "arrangements" in the cyclooxygenase active site of native oPGHS-1 in which the 13-proS hydrogen is removed in the rate-determining step, but from which oxygenation and cyclization proceed differently to form PGG 2 , 11R-HETE, or a combination of 15S-and 15R-HETE depending on the arrangement of arachidonate at the instant of hydrogen abstraction. These arrangements could involve subtle differences in carbon chain conformations, differences in electrostatics along the carbon chain of arachidonate or in active site residues or perhaps, most likely, a combination of these factors. For example, a conformation of arachidonate having an optimal orientation of C-9 with respect to C-11 would result in formation of the C-9 to C-11 endoperoxide and proceed to PGG 2 ; alternatively, if the distance between C-9 and C-11 is not optimal (either too great or too near), the incipient 11-peroxyl radical could not proceed to the endoperoxide but would yield the 11-hydroperoxide as the abortive product. Previous studies have shown that 11-hydroperoxide product, 11-HPETE, is not converted to PGG 2 by oPGHS-1 (45) .
There are two general possibilities that could account for the fact that different products are formed with different K m and V max (Fig. 7, A and B (Schemes 1 and 2, respectively) ). One possibility is that there is essentially one form of the enzyme (E) that binds arachidonate and that, secondarily, rearrangements of the substrate (and/or enzyme) occur after the substrate becomes bound, which then proceed to product (Scheme 1). The other general possibility is that different starting forms of the enzyme occur (E 1 and E 2 ), which bind substrate differently and yield different products (Scheme 2). As a test of these two possibilities, we determined the IC 50 values for inhibition (26, 31, 32) . We found that oPGHS-1 forms an additional product, 15S-HETE, which is apparently not produced from arachidonate by PGHS-2 (32). In fact, 15S-HETE is the predominant 15-HETE enantiomer formed by oPGHS-1, whereas both PGHS-2 and aspirin-acetylated PGHS-2 form almost exclusively 15R-HETE (32, 33) .
Both 15S-HETE and 15R-HETE would be expected to be formed under conditions favoring a combination of formation of 15-arachidonyl radical and O 2 access to C-15. Formation of 15R-HETE by aspirin-acetylated PGHS-2 involves abstraction of the 13-proS hydrogen (49) , as does formation of PGG 2 (and presumably 11R-HETE and 15S-HETE) (26, 31) . We assume, therefore, that the 15R-HETE formed in our experiments involves abstraction of this same prochiral hydrogen. The 15S-/ 15R-HETE ratio remained constant for 15-HETE synthesized by oPGHS-1 at arachidonate concentrations between 2 and 100 M arachidonate. This was also true with the V349L oPGHS-1 mutant. Collectively, this information suggests that 15S-and 15R-HETE derive from the same arrangement of arachidonate in the cyclooxygenase site and that the 15S-/15R-HETE ratio simply reflects positional access of O 2 to a 15-arachidonyl radical formed by removal of the 13-proS hydrogen. Although antarafacial O 2 addition is observed in most lipoxygenase reactions, there is recent precedent for a suprafacial O 2 addition with a fungal lipoxygenase (46) .
The side chain of Val-349 protrudes into the cyclooxygenase active site approximately opposite the side chain of Ser-530, the site of aspirin acetylation (36, 47, 48) . Our results indicate that replacing Val-349 with the larger leucine has the overall effects of decreasing the amounts of products formed as a result of O 2 insertion at C-11 (PGG 2 and 11-HETE) and increasing the amount of product involving O 2 insertion at C-15 (15-HETE), i.e. with the V349L mutant, arrangements of arachidonate in the active site that lead to O 2 insertion at C-11 become relatively less favorable than in native oPGHS-1. The K m for PGG 2 formation is increased and PGG 2 and 11-HETE formation occurs to a significantly decreased extent with V349L oPGHS-1. In contrast, O 2 access to C-15 is relatively enhanced with a relative increase in the rate of monooxygenation at C-15 and a relative decrease in the K m for 15-HETE production.
We have emphasized in this report the fact that oPGHS-1 forms products other than PGG 2 . However, in concluding, we point out that the K m and V max values favor the synthesis of this endoperoxide over monohydroxy acids by native oPGHS-1. At arachidonate concentrations (Յ2 M) expected to be most relevant physiologically, PGG 2 represents Ͼ95% of the total oxygenated product. FIG. 7 . Kinetic schemes for the binding of arachidonate to a single enzyme form and for the binding of arachidonate to a mixture of different enzyme forms. A shows Scheme 1; arachidonate enters a static cyclooxygenase active site and then can assume alternative conformations or arrangements leading to different products (e.g. PGG 2 , 11-HETE, or 15-HETE). This scheme and its equations also apply to situations where arachidonate binding induces changes in the active site. B shows Scheme 2; arachidonate binds to different forms of the cyclooxygenase active site, which catalyze the formation of different products. A variation of this scheme applies to situations in which different forms of the enzyme bind different forms of the substrate to produce different products.
